Aeglea BioTherapeutics, Inc.

Home » Aeglea BioTherapeutics, Inc.

Secondary

Aeglea BioTherapeutics, Inc.

We are a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer.

Symbol

AGLE

Final Price
$9.01

Shares
4,500,000

Anticipated Date
TBD

Underwriters
Evercore ISI, BMO Capital Markets, Jones Trading

To view the prospectus for Aeglea BioTherapeutics, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253